SANOFI SECURES ENTRY INTO U.S. PHARMACEUTICAL MARKET WITH BUY- OUT OF Rx JOINT VENTURE WITH STERLING; $1.68 BIL. IN CASH PLUS INTEREST IN EUROPEAN OTCs IS PRICE
Sanofi is paying Kodak $1.68 bil. in cash to hold on to its entry into the U.S. prescription drug market through Sterling.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth